Answers are grounded in this paper and cite their sources.
Synaptic dysfunction is an important early feature of Alzheimer’s disease (AD) and Parkinson’s disease (PD), in which impaired long-term potentiation (LTP), long-term depression (LTD) and metaplasticity accompany disturbances in postsynaptic phosphosignalling. Neuroproteomic studies implicate receptor phosphorylation, kinase–phosphatase imbalance, cytoskeletal remodelling and neuromodulator-dependent pathways in these deficits. Alongside the NMDAR–CaMKII–PSD-95 axis, acetylcholine- and glutamate-regulated small-GTPase cascades provide mechanistic links between biochemical signalling and dendritic spine plasticity. Advances in graphene-based neuromorphic devices demonstrate programmable conductance states and electrical analogues of synaptic learning, suggesting a possible engineering framework informed by molecular disease signatures. This narrative review critically examines synaptic phosphoproteomic alterations in AD and PD, their implications for designing phosphoprotein-functionalised graphene interfaces, and the conceptual integration of glutamatergic and neuromodulatory inputs into device operation. Importantly, electronic emulation of LTP/LTD has not established restoration of endogenous phosphorylation networks, synaptic incorporation or therapeutic efficacy in AD or PD. We distinguish demonstrated molecular and materials findings from the proposed biochemical-to-electronic coupling mechanisms and discuss the experimental, biological and translational limitations that must be resolved before disease-specific synaptic repair can be evaluated.
No takes yet. Share an insight, caveat, or question.
Vinay et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: